Clinical Trial Update: Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating a triplet of bortezomib, lenalidomide, and dexamethasone in relapsed or relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-09